Head to Head Survey: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)

Crispr Theraptc (NASDAQ: CRSP) and Exact Sciences Corporation (NASDAQ:EXAS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Analyst Ratings

This is a breakdown of current ratings and target prices for Crispr Theraptc and Exact Sciences Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Crispr Theraptc 0 4 4 0 2.50
Exact Sciences Corporation 0 5 8 0 2.62

Crispr Theraptc currently has a consensus target price of $23.08, indicating a potential upside of 30.05%. Exact Sciences Corporation has a consensus target price of $50.77, indicating a potential downside of 12.80%. Given Crispr Theraptc’s higher probable upside, equities research analysts clearly believe Crispr Theraptc is more favorable than Exact Sciences Corporation.

Institutional and Insider Ownership

25.6% of Crispr Theraptc shares are owned by institutional investors. Comparatively, 85.7% of Exact Sciences Corporation shares are owned by institutional investors. 40.0% of Crispr Theraptc shares are owned by insiders. Comparatively, 4.0% of Exact Sciences Corporation shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Crispr Theraptc and Exact Sciences Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Crispr Theraptc $5.16 million 141.11 -$23.17 million ($1.32) -13.45
Exact Sciences Corporation $99.38 million 70.14 -$167.21 million ($1.16) -50.19

Crispr Theraptc has higher revenue, but lower earnings than Exact Sciences Corporation. Exact Sciences Corporation is trading at a lower price-to-earnings ratio than Crispr Theraptc, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Crispr Theraptc and Exact Sciences Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Crispr Theraptc -466.58% -38.42% -25.26%
Exact Sciences Corporation -60.71% -30.32% -27.37%

Summary

Exact Sciences Corporation beats Crispr Theraptc on 7 of the 12 factors compared between the two stocks.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply